Clinical Trials Directory

Trials / Unknown

UnknownNCT04212312

Single Versus Repeat Betamethasone in Twin Pregnancies

Repeat Versus Single Course of Betamethasone in Twin Pregnancies

Status
Unknown
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
Female
Age
Healthy volunteers

Summary

Thus far no robust data exist as to the effect of repeted course of antenatal corticosteroids in twin pregnancies. The investigators hypothesized that repeat course of betamethasone would further reduce neonatal morbidity in twins born before 34 weeks' gestation when compared with single dose.

Detailed description

Observational data suggest benefits in multiple gestations exposed to antenatal corticosteroids, although these studies have not consistently reported a statistical benefit or the benefits achieved in singletons. Nevertheless, based on the improved outcomes reported in singleton gestations, one course of antenatal corticosteroids is administered to all patients who are between 24 weeks and 34 weeks of gestation and at risk of delivery within 7 days, irrespective of the fetal number. Moreover, "a repeat course" of antenatal corticosteroids should also be considered in women who are less than 34 weeks of gestation who have an imminent risk of preterm delivery within the next 7 days, and whose prior course of antenatal corticosteroids was administered more than 14 days previously, again, irrespective of the fetal number. The objective of the current study is to evaluate fetal outcomes in twin pregnancies following repeat betamethasone administration during pregnancy.

Conditions

Timeline

Start date
2020-02-01
Primary completion
2020-12-01
Completion
2021-01-01
First posted
2019-12-26
Last updated
2019-12-26

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT04212312. Inclusion in this directory is not an endorsement.